NASDAQ:OMER Omeros Q3 2026 Earnings Date & Estimates $17.49 -0.66 (-3.66%) As of 10:08 AM Eastern This is a fair market value price provided by Massive. Learn more. Omeros is scheduled to report Q3 2026 earnings on Monday, November 16, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 16, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Omeros in Q3 2026Omeros is expected to post earnings of $0.02 per share on revenue of $37.28 million. In the same quarter a year earlier Omeros reported -$0.19 per share. Omeros last reported on August 12, 2026, posting $0.02 per share and beating the -$0.2683 consensus estimate. Omeros has beaten the consensus EPS estimate in 6 of its last 8 quarters.Consensus EstimatesConsensus EPS$0.02Expected Revenue$37.28 millionPrior-Year EPS-$0.19Recent Track RecordLast ReportedQ2 2026Last Quarter EPS$0.02 (Beat by +$0.2883)Last Quarter Revenue$28.53 millionEPS Beat Rate6 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Omeros Q3 2026 Earnings FAQ When does Omeros report Q3 2026 earnings? Omeros (NASDAQ:OMER) has confirmed it will report Q3 2026 earnings on Monday, November 16, 2026, after market closes. What time is Omeros' Q3 2026 earnings call? Omeros' Q3 2026 earnings conference call is scheduled for Monday, November 16, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Omeros? Analysts expect Omeros to post earnings of $0.02 per share for Q3 2026. How much revenue is Omeros expected to report? The consensus revenue estimate for Omeros is $37.28 million for Q3 2026. Omeros Earnings HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMERNovember 10 at 5:48 PM | globenewswire.comOmeros Corporation to Announce Third Quarter Financial Results on November 16, 2026November 10 at 4:02 PM | businesswire.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 12 at 1:00 AM | Behind the Markets (Ad)INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMERNovember 5, 2026 | prnewswire.comOmeros (OMER) Projected to Announce Earnings on ThursdayNovember 5, 2026 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMERNovember 3, 2026 | globenewswire.comSee More Omeros Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Omeros? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Omeros and other key companies, straight to your email. Email Address About OmerosOmeros (NASDAQ:OMER) (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994. Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway. Omeros conducts research and clinical development primarily from the United States, with clinical programs potentially involving international sites. Gregory A. Demopulos, M.D., is the company’s founder, chairman and chief executive officer. View Omeros ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keeping AI Cool: AAON Rides the AI Heatwave to Record GrowthPalantir’s Real Washington Risk Isn’t the Budget—It’s OversightCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandAST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn't Going Away Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
